These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3383550)

  • 1. Optimal cefotaxime dosing for gram-negative bacteremia: effective trough serum bactericidal titers and drug concentrations 8 and 12 hr after 1- or 2-gm infusions.
    Goodpasture HC; Gerlach EH; Jones RN; Peterie JD
    Diagn Microbiol Infect Dis; 1988 Feb; 9(2):97-103. PubMed ID: 3383550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of three different dosing regimens of cefotaxime for treatment of gram-negative bacteremia.
    Trenholme GM; Schmitt BA; Nelson JA; Gvazdinskas LC; Harrison BB; Parkhurst GW
    Diagn Microbiol Infect Dis; 1989; 12(1):107-11. PubMed ID: 2653713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic (kinetic) considerations in the treatment of moderately severe infections with cefotaxime.
    Turnidge JD
    Diagn Microbiol Infect Dis; 1995; 22(1-2):57-69. PubMed ID: 7587052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic options for cefotaxime in the management of bacterial infections.
    Raddatz JK; Ostergaard BE; Rotschafer JC
    Diagn Microbiol Infect Dis; 1995; 22(1-2):77-83. PubMed ID: 7587054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic killing of gram-negative bacilli by cefotaxime, its desacetyl metabolite and human polymorphonuclear neutrophils.
    Mandell LA; Afnan M
    J Antimicrob Chemother; 1991 Jun; 27(6):817-28. PubMed ID: 1938688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical laboratory approach for estimating effective administrative dosage of cefmenoxime. Observation on the MICS and cefmenoxime disc susceptibility test].
    Uete T; Matsuo K
    Jpn J Antibiot; 1984 May; 37(5):791-801. PubMed ID: 6090721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of cefotaxime and latamoxef for Escherichia coli bacteremia and meningitis in newborn rats.
    Kim KS; Manocchio M; Bayer AS
    Chemotherapy; 1984; 30(4):262-9. PubMed ID: 6086247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Criteria for testing the susceptibility of Streptococcus pneumoniae to cefotaxime and its desacetyl metabolite using 1 microgram or 30 micrograms cefotaxime disks.
    Barry AL; Brown SD; Novick WJ
    Eur J Clin Microbiol Infect Dis; 1995 Aug; 14(8):724-6. PubMed ID: 8565996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of in vitro activity of cefotaxime and desacetylcefotaxime alone and in combination against 320 gram-negative clinical isolates.
    Piédrola G; Galan I; Leyva A; Maroto MC
    Drugs; 1988; 35 Suppl 2():62-4. PubMed ID: 3135171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of cefotaxime in gram-negative meningitis.
    LeFrock JL; Molavi A; Smith B; Black P; Rosenberg M; Rolston K; Brodner R; Chandrasekar P; Henao L; Kannangara DW
    Neurosurgery; 1984 Nov; 15(5):679-82. PubMed ID: 6095133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects.
    Barriere SL; Ozasa DC; Mordenti J
    Antimicrob Agents Chemother; 1985 Jul; 28(1):55-7. PubMed ID: 3929680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic interaction of cefotaxime and its metabolite desacetylcefotaxime demonstrated by drug-impregnated disks.
    Stevens DL; Bergstrom R; Gibbons A
    Diagn Microbiol Infect Dis; 1989; 12(1):73-80. PubMed ID: 2653715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefotaxime monotherapy in septicemic patients with hematological malignancies.
    Plesner AM; Hansen MM; Nissen NI; Friis H
    Clin Ther; 1986; 9(1):97-105. PubMed ID: 3815462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of cefotaxime and desacetylcefotaxime against pathogenic bacteria. Assessment with the serum bactericidal test.
    Reller LB
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):55S-61S. PubMed ID: 6086219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftriaxone against gram-negative and gram-positive bacteria: bactericidal and post-antibiotic effect.
    Ravizzola G; Bonfanti C; Savoldi E; Turano A
    Chemioterapia; 1985 Jun; 4(3):204-8. PubMed ID: 3875430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics of cefotaxime and ceftizoxime and the role of desacetylcefotaxime in the antibacterial activity of cefotaxime.
    Quintiliani R; Nightingale CH; Tilton R
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):63S-70S. PubMed ID: 6086220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antibacterial activity of ceftizoxime against gram-negative strains.
    Debbia E; Soro O
    Chemioterapia; 1985 Apr; 4(2):166-9. PubMed ID: 3891115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activity of the new oral cephalosporin cefixime.
    Counts GW; Baugher LK; Ulness BK; Hamilton DJ
    Eur J Clin Microbiol Infect Dis; 1988 Jun; 7(3):428-31. PubMed ID: 3137053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.
    Knothe H; Shah PM; Eckardt O
    Infection; 1991; 19(5):370-6. PubMed ID: 1800379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics.
    Nix DE; Schentag JJ
    Diagn Microbiol Infect Dis; 1995; 22(1-2):71-6. PubMed ID: 7587053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.